Jansen, Yanina http://orcid.org/0000-0002-8322-9841
Kruse, Vibeke
Corthals, Jurgen
Schats, Kelly
van Dam, Pieter-Jan
Seremet, Teofila
Heirman, Carlo
Brochez, Lieve
Kockx, Mark
Thielemans, Kris
Neyns, Bart
Funding for this research was provided by:
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering Belgium (not applicable)
Article History
Received: 28 October 2019
Accepted: 19 May 2020
First Online: 26 June 2020
Compliance with ethical standards
:
: Yanina Jansen received travel grant support from BMS, MSD, Pfizer. Vibeke Kruse provided consultation, attended advisory boards, and/or provided lectures for: Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen and Sanofi. My institution received honoraria for my contribution. Jurgen Corthals has no conflict of interest. Kelly Schats: KS is an employee of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Pieter-Jan Van Dam4: PJ Van Dam is an employee of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Teofila Seremet received congresses and advisory fees from Novartis and one preceptorship MSD. Carlo Heirman: CH is an inventor on patents related to TriMix and is employee of eTheRNA ImmunoTherapies and may therefore have a financial interest in the development of TriMix technologies. Lieve Brochez: Advisory Board Incyte 6/2017, Value-based health care project sponsored by Amgen. Mark Kockx: Mark Kockx is the CEO of HistoGeneX NV which performs immunohistochemical and molecular testing for pharmaceutical companies as part of (pre-) clinical studies that evaluate new anticancer drugs. There is no other relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Kris Thielemans: KT is an inventor on patents related to TriMix and DC technology and is consultant for eTheRNA ImmunoTherapies and may therefore has a financial interest in the development of TriMix technologies. Bart Neyns: Honoraria-Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche. Consulting or Advisory Role-Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche. Speakers’ Bureau-Novartis. Travel, Accommodations, Expenses-Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche.
: This trial was approved by the Institutional Ethics Committee of the UZ Brussel (ClinicalTrials.gov identifier: NCT01676779). All patients provided signed informed consent.